1Poddar N, Wang JC. Thrombotic thrombocytopenic purpura in a patient with interferon treated hepatitis C successfully treated with rituximab[J].Hematol Rep, 2013,5 (1) : 5.
2Wu N, Liu J, Yang S, et al. Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thromboeytopenic purpura[J].Transfusion,2015,55(1):18.
3Scully M,Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome [J]. Br J Haematol,2014,164(6):759.
4LottaLA,WuHM. The emerging concept of residual ADAMTS13 activity in ADAMTS13-deficient thrombotic thrombocytopenic- purpura[J]. Blood,2013,27(2) :71.
5McMinn JR, George .IN. Evaluation of women with clinical sus- pected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregence[J]. J Clin Apher,2001,16(4):202.
6Sayani FA,Abrams CS. How I treat refractory thrombotic throm- bocytopenic purpura[J]. Blood,2015,125(25) :3860.
7Scully M,McDonald V. A phase II study of the safety and efficacy of rit- uximab with plasma exchange in acute acquired thrombotic thrombocy- topenic purpura[J]. Blood, 2011,118(7) : 1746.
8Froissart A, Buffet M, Veyradier A. First-line rituximab efficacy and safety in patients with acquired idiopathic thrombotic throm- bocytopenic purpura experiencing a suboptimal response to thera- peutical plasma exchange~ results of a prospective multicenter phase 2 study[J]. Crit Care Med,2012,40(1) :104.
9Peyvandi F,Scully M, Kremer Hovinga JA, et al. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura[J]. N Engl J Med,2016,374(6) :511.
